Impact of prolonged sepsis on neural and muscular components of muscle contractions in a mouse model.


Journal

Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883

Informations de publication

Date de publication:
04 2021
Historique:
revised: 19 11 2020
received: 16 09 2020
accepted: 16 12 2020
pubmed: 20 1 2021
medline: 29 10 2021
entrez: 19 1 2021
Statut: ppublish

Résumé

Prolonged critically ill patients frequently develop debilitating muscle weakness that can affect both peripheral nerves and skeletal muscle. In-depth knowledge on the temporal contribution of neural and muscular components to muscle weakness is currently incomplete. We used a fluid-resuscitated, antibiotic-treated, parenterally fed murine model of prolonged (5 days) sepsis-induced muscle weakness (caecal ligation and puncture; n = 148). Electromyography (EMG) measurements were performed in two nerve-muscle complexes, combined with histological analysis of neuromuscular junction denervation, axonal degeneration, and demyelination. In situ muscle force measurements distinguished neural from muscular contribution to reduced muscle force generation. In myofibres, imaging and biomechanics were combined to evaluate myofibrillar contractile calcium sensitivity, sarcomere organization, and fibre structural properties. Myosin and actin protein content and titin gene expression were measured on the whole muscle. Five days of sepsis resulted in increased EMG latency (P = 0.006) and decreased EMG amplitude (P < 0.0001) in the dorsal caudal tail nerve-tail complex, whereas only EMG amplitude was affected in the sciatic nerve-gastrocnemius muscle complex (P < 0.0001). Myelin sheath abnormalities (P = 0.2), axonal degeneration (number of axons; P = 0.4), and neuromuscular junction denervation (P = 0.09) were largely absent in response to sepsis, but signs of axonal swelling [higher axon area (P < 0.0001) and g-ratio (P = 0.03)] were observed. A reduction in maximal muscle force was present after indirect nerve stimulation (P = 0.007) and after direct muscle stimulation (P = 0.03). The degree of force reduction was similar with both stimulations (P = 0.2), identifying skeletal muscle, but not peripheral nerves, as the main contributor to muscle weakness. Myofibrillar calcium sensitivity of the contractile apparatus was unaffected by sepsis (P ≥ 0.6), whereas septic myofibres displayed disorganized sarcomeres (P < 0.0001) and altered myofibre axial elasticity (P < 0.0001). Septic myofibres suffered from increased rupturing in a passive stretching protocol (25% more than control myofibres; P = 0.04), which was associated with impaired myofibre active force generation (P = 0.04), linking altered myofibre integrity to function. Sepsis also caused a reduction in muscle titin gene expression (P = 0.04) and myosin and actin protein content (P = 0.05), but not the myosin-to-actin ratio (P = 0.7). Prolonged sepsis-induced muscle weakness may predominantly be related to a disruption in myofibrillar cytoarchitectural structure, rather than to neural abnormalities.

Sections du résumé

BACKGROUND
Prolonged critically ill patients frequently develop debilitating muscle weakness that can affect both peripheral nerves and skeletal muscle. In-depth knowledge on the temporal contribution of neural and muscular components to muscle weakness is currently incomplete.
METHODS
We used a fluid-resuscitated, antibiotic-treated, parenterally fed murine model of prolonged (5 days) sepsis-induced muscle weakness (caecal ligation and puncture; n = 148). Electromyography (EMG) measurements were performed in two nerve-muscle complexes, combined with histological analysis of neuromuscular junction denervation, axonal degeneration, and demyelination. In situ muscle force measurements distinguished neural from muscular contribution to reduced muscle force generation. In myofibres, imaging and biomechanics were combined to evaluate myofibrillar contractile calcium sensitivity, sarcomere organization, and fibre structural properties. Myosin and actin protein content and titin gene expression were measured on the whole muscle.
RESULTS
Five days of sepsis resulted in increased EMG latency (P = 0.006) and decreased EMG amplitude (P < 0.0001) in the dorsal caudal tail nerve-tail complex, whereas only EMG amplitude was affected in the sciatic nerve-gastrocnemius muscle complex (P < 0.0001). Myelin sheath abnormalities (P = 0.2), axonal degeneration (number of axons; P = 0.4), and neuromuscular junction denervation (P = 0.09) were largely absent in response to sepsis, but signs of axonal swelling [higher axon area (P < 0.0001) and g-ratio (P = 0.03)] were observed. A reduction in maximal muscle force was present after indirect nerve stimulation (P = 0.007) and after direct muscle stimulation (P = 0.03). The degree of force reduction was similar with both stimulations (P = 0.2), identifying skeletal muscle, but not peripheral nerves, as the main contributor to muscle weakness. Myofibrillar calcium sensitivity of the contractile apparatus was unaffected by sepsis (P ≥ 0.6), whereas septic myofibres displayed disorganized sarcomeres (P < 0.0001) and altered myofibre axial elasticity (P < 0.0001). Septic myofibres suffered from increased rupturing in a passive stretching protocol (25% more than control myofibres; P = 0.04), which was associated with impaired myofibre active force generation (P = 0.04), linking altered myofibre integrity to function. Sepsis also caused a reduction in muscle titin gene expression (P = 0.04) and myosin and actin protein content (P = 0.05), but not the myosin-to-actin ratio (P = 0.7).
CONCLUSIONS
Prolonged sepsis-induced muscle weakness may predominantly be related to a disruption in myofibrillar cytoarchitectural structure, rather than to neural abnormalities.

Identifiants

pubmed: 33465304
doi: 10.1002/jcsm.12668
pmc: PMC8061378
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

443-455

Informations de copyright

© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders.

Références

Crit Care. 2012 Oct 26;16(5):R209
pubmed: 23098317
Crit Care Med. 2007 Feb;35(2):351-7
pubmed: 17205014
Am J Respir Crit Care Med. 2013 Feb 1;187(3):238-46
pubmed: 23204256
Crit Care. 2019 Jul 1;23(1):236
pubmed: 31262340
Clin Sci (Lond). 2012 Feb;122(3):133-42
pubmed: 21880013
Chest. 1991 Jan;99(1):176-84
pubmed: 1845860
J Cachexia Sarcopenia Muscle. 2020 Feb;11(1):103-119
pubmed: 31441598
Light Sci Appl. 2018 Oct 24;7:79
pubmed: 30374401
Adv Exp Med Biol. 2010;682:105-22
pubmed: 20824522
J Pathol. 2013 Feb;229(3):477-85
pubmed: 23132094
Physiol Rev. 2015 Jul;95(3):1025-109
pubmed: 26133937
Crit Care Med. 2015 Aug;43(8):1603-11
pubmed: 25882765
Crit Care Med. 2012 Jan;40(1):79-89
pubmed: 21926599
Intensive Care Med Exp. 2018 Aug 14;6(1):26
pubmed: 30112605
J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1143-1145
pubmed: 31661195
Sci Rep. 2017 May 3;7(1):1391
pubmed: 28469177
Am J Respir Crit Care Med. 2007 Mar 1;175(5):480-9
pubmed: 17138955
Lancet. 2002 Jul 20;360(9328):219-23
pubmed: 12133657
Thorax. 2018 Oct;73(10):926-935
pubmed: 29980655
J Vis Exp. 2017 May 2;(123):
pubmed: 28518095
Intensive Care Med. 2003 Sep;29(9):1505-14
pubmed: 12879242
J Cachexia Sarcopenia Muscle. 2017 Feb;8(1):89-101
pubmed: 27897405
J Neurol Neurosurg Psychiatry. 2011 Mar;82(3):287-93
pubmed: 20802220
Intensive Care Med Exp. 2016 Dec;4(1):10
pubmed: 27207148
Crit Care Med. 2003 Apr;31(4):1012-6
pubmed: 12682465
Muscle Nerve. 2002 Oct;26(4):499-505
pubmed: 12362415
Neurology. 2003 Sep 9;61(5):631-6
pubmed: 12963753
J Clin Invest. 2009 May;119(5):1150-8
pubmed: 19425168
Biosens Bioelectron. 2019 Aug 1;138:111284
pubmed: 31103932
J Cachexia Sarcopenia Muscle. 2010 Dec;1(2):147-157
pubmed: 21475702
Brain. 1987 Aug;110 ( Pt 4):819-41
pubmed: 3651796
PLoS One. 2019 Oct 3;14(10):e0223185
pubmed: 31581205
J Cachexia Sarcopenia Muscle. 2020 Dec;11(6):1399-1412
pubmed: 32893974
J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):734-747
pubmed: 31016887
J Crit Care. 2015 Oct;30(5):1151.e9-14
pubmed: 26211979
Crit Care. 2019 Jan 29;23(1):33
pubmed: 30696473
J Physiol. 2011 Apr 15;589(Pt 8):2007-26
pubmed: 21320889
Am J Respir Cell Mol Biol. 2014 Jun;50(6):1096-106
pubmed: 24400695
Intensive Care Med. 2014 Apr;40(4):528-38
pubmed: 24531339
BMC Genomics. 2011 Dec 13;12:602
pubmed: 22165895
Crit Care. 2016 Aug 10;20(1):254
pubmed: 27510990
Front Physiol. 2016 Feb 04;7:23
pubmed: 26869939
Muscle Nerve. 2010 Jun;41(6):850-6
pubmed: 20151466
Biosens Bioelectron. 2018 Apr 15;102:589-599
pubmed: 29245144
Biophys J. 2010 Feb 17;98(4):606-16
pubmed: 20159157
Crit Care Med. 2008 May;36(5):1559-63
pubmed: 18434889
JAMA. 2013 Oct 16;310(15):1591-600
pubmed: 24108501
Nat Commun. 2020 Sep 8;11(1):4479
pubmed: 32900999
Crit Care Med. 2012 Feb;40(2):647-50
pubmed: 21963579
PLoS One. 2011 Mar 31;6(3):e18090
pubmed: 21483870
Neurology. 2006 Oct 24;67(8):1421-5
pubmed: 17060568
J Cachexia Sarcopenia Muscle. 2021 Apr;12(2):443-455
pubmed: 33465304
J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):500-6
pubmed: 16306155
Lancet. 1996 Jun 8;347(9015):1579-82
pubmed: 8667865

Auteurs

Chloë Goossens (C)

Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Ruben Weckx (R)

Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Sarah Derde (S)

Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Lawrence Van Helleputte (L)

Experimental Neurology and Leuven Brain Institute, Department of Neurosciences, KU Leuven, Leuven, Belgium.
Laboratory of Neurobiology, VIB Center for Brain & Disease Research, Leuven, Belgium.

Dominik Schneidereit (D)

Institute of Medical Biotechnology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

Michael Haug (M)

Institute of Medical Biotechnology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

Barbara Reischl (B)

Institute of Medical Biotechnology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

Oliver Friedrich (O)

Institute of Medical Biotechnology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

Ludo Van Den Bosch (L)

Experimental Neurology and Leuven Brain Institute, Department of Neurosciences, KU Leuven, Leuven, Belgium.
Laboratory of Neurobiology, VIB Center for Brain & Disease Research, Leuven, Belgium.

Greet Van den Berghe (G)

Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Lies Langouche (L)

Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH